尼克洛萨米德和甲胺组合在ApcMin/+小鼠中的剂量反应关系:一个集成的体外和药理学建模研究
Joyeon Kang1,2, Dong Keon Kim1, Yoojeong Seo1,2
1Division of Gastroenterology, Department of Internal Medicine, Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Gut and liver
|December 9, 2025
概括
尼克洛萨米德100毫克/千克和美特福林的组合有效地减少了家族腺瘤多重症 (FAP) 的小鼠模型中的息肉. 这一发现支持FAP化疗预防的进一步临床研究.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 家族性腺瘤多重症 (FAP) 是一种与APC基因突变相关的遗传性结直肠癌综合征.
- FAP的特点是许多结直肠多体和早期发作的癌症.
研究的目的:
- 在小鼠FAP模型中评估结合尼克洛萨米德和美特福林的化学预防疗效.
- 为了确定最佳的剂量和评估药物相互作用,以潜在的FAP管理.
主要方法:
- ApcMin/+小鼠接受了不同剂量的尼古洛萨米德和美特福林治疗,单独或组合,持续了16周.
- 测量了多体负担,并使用Bliss独立性和PBPK建模分析了药物相互作用.
主要成果:
- 高剂量 (100和200毫克/公斤) 的尼克洛萨米德和甲胺显著减少了多的数量.
- 100毫克/千克组合显示与安全的甲福林暴露具有添加效应,而200毫克/千克显示对抗性并超过安全值.
- PBPK建模表明尼古洛萨米德会增加甲胺的暴露.
结论:
- 尼克洛萨米德和甲胺的100毫克/千克组合被确定为小鼠FAP模型中化学预防的最佳剂量.
- 这项研究为FAP管理中的临床转化提供了理由.
更多相关视频
10:39Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
13.8K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.7K
相关概念视频
Measurement of Bioavailability: Pharmacodynamic Methods
217
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
217
Dose-Response Relationship: Potency and Efficacy
6.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.3K
